Keyword: Shionogi

Because the two thrombocytopenia drugs are similar in efficacy, safety and convenience profiles, the competition will come down to access and pricing.

A phase 3 trial of Roche’s possible Tamiflu replacement in people at high risk of complications from the flu is meeting its goals.

If approved, baloxavir marboxil (marketed as Xofluza in Japan), will be the first flu drug with a new mechanism approved in the U.S. in over 20 years.

Dova and its brand-new Doptelet could soon face off against Shionogi’s lusutrombopag, set for an FDA decision in August

Shionogi’s flu drug won Japanese approval; Sun Pharma's Halol plant was cited by the FDA; EpimAb hired a top Novartis researcher as CMO; plus more.

Shionogi's Roche-partnered Xofluza, a one-time, single-dose regimen, probably won't win U.S. approval till next winter.

ViiV Healthcare is taking its history in HIV treatment and community involvement to the small screen.

WuXi AppTec started IPO prep for core drug R&D, Purdue and Shionogi won approval for a new constipation med, and an Indian CRO's meds were halted by EMA.

With the FDA's approval of Purdue and Shionogi's Symproic, there's now a third competitor prepping to jump into the opioid-induced constipation market.